Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy?


Journal

Urologic oncology
ISSN: 1873-2496
Titre abrégé: Urol Oncol
Pays: United States
ID NLM: 9805460

Informations de publication

Date de publication:
06 2022
Historique:
received: 21 10 2021
revised: 23 12 2021
accepted: 15 01 2022
pubmed: 27 2 2022
medline: 18 5 2022
entrez: 26 2 2022
Statut: ppublish

Résumé

To compare the accuracy in detecting variant histologies (VH) at transurethral resection of bladder (TURB) and radical cystectomy (RC) specimen among tertiary referral centres, in order to investigate potential reasons of discrepancies from the pathological point of view. Clinical and histopathological data of TURB specimen and subsequent cystectomy specimen of 3,445 RC candidate patients have been retrospectively collected from 24 tertiary referral centres between 1980 and 2021. VH considered in the analysis were pure squamous cell carcinoma, urothelial carcinoma with squamous differentiation, pure adenocarcinoma, urothelial carcinoma with glandular differentiation, micropapillary bladder cancer (BCa), neuroendocrine BCa, and other variants. The degree of agreement between TURB and RC concerning the identification of VH was expressed as concordance, classified according to Cohen's kappa coefficient. A VH was reported in 17% of TURB specimens, 45% of which were not confirmed in RC. The lowest concordance rate was reported for micropapillary BCa with 11 out of 18 (61%) centres reporting no agreement, whereas neuroendocrine BCa achieved the highest concordance rate with only 3 centres (17%) reporting no agreement. Our results shows that even among centres with the advantage of a referent uropathologist the micropapillary variant is characterized by scarce accuracy between TURB and RC. Differences in TURB specimen acquisition by the urologist and in sampling methods among different centres are the main limitations of the study. Accuracy of TURB in detecting VH is poor for certain VH, in particular for micropapillary BCa, with evident variation among centres. Novel diagnostic tools are required to better identify these VH and drive patients toward a personalized treatment.

Identifiants

pubmed: 35216892
pii: S1078-1439(22)00026-6
doi: 10.1016/j.urolonc.2022.01.008
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

273.e11-273.e20

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Auteurs

Alessia Cimadamore (A)

Section of Pathological Anatomy, School of Medicine, Polytechnic University of the Marche Region, United Hospitals, Ancona, Italy. Electronic address: a.cimadamore@staff.univpm.it.

Chiara Lonati (C)

Department of Urology, Spedali Civili di Brescia, Brescia, Italy; Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.

Ettore Di Trapani (E)

Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy.

Ottavio De Cobelli (O)

Department of Urology, IEO European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Hematology-Oncology, Università degli Studi di Milano, Milan, Italy.

Michael Rink (M)

Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Stefania Zamboni (S)

Department of Urology, Spedali Civili di Brescia, Brescia, Italy.

Claudio Simeone (C)

Department of Urology, Spedali Civili di Brescia, Brescia, Italy.

Francesco Soria (F)

Division of Urology, Department of Surgical Sciences, AOU Città della Salute e della Scienza di Torino, Torino School of Medicine, Torino, Italy.

Alberto Briganti (A)

Department of Medical Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; University Vita-Salute San Raffaele, Milan, Italy.

Francesco Montorsi (F)

Department of Medical Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy; University Vita-Salute San Raffaele, Milan, Italy.

Luca Afferi (L)

Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.

Agostino Mattei (A)

Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland.

Roberto Carando (R)

Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; Clinica Luganese Moncucco, Lugano, Switzerland; Clinica S. Anna, Swiss Medical Group, Sorengo, Switzerland; Clinica Santa Chiara, Locarno, Switzerland.

Paola Irene Ornaghi (PI)

Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Alessandro Tafuri (A)

Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Alessandro Antonelli (A)

Department of Urology, Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy.

Robert J Karnes (RJ)

Department of Urology, Mayo Clinic, Rochester, MN.

Anna Colomer (A)

Department of Urology, Institut Mutualiste Montsouris and Universitè Paris Descartes, Paris, France.

Rafael Sanchez-Salas (R)

Department of Urology, Institut Mutualiste Montsouris and Universitè Paris Descartes, Paris, France.

Roberto Contieri (R)

Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Rodolfo Hurle (R)

Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.

Cédric Poyet (C)

Department of Urology, University Hospital Zürich, Zürich, Switzerland.

Giuseppe Simone (G)

Department of Urology, "Regina Elena" National Cancer Institute, IRCCS, Rome, Italy.

David D'Andrea (D)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria.

Shahrokh F Shariat (SF)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Department of Urology, Second Faculty of Medicine, Charles University, Prague, Czech Republic.

Antonio Galfano (A)

Department of Urology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy.

Paolo Umari (P)

Division of Surgery and Interventional Science, University College London, London, UK.

Simone Francavilla (S)

Urology Unit, Surgical Department, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy.

Mathieu Roumiguie (M)

Department of Urology, University Hospital of Toulouse Rangueil, Toulouse, France.

Carlo Terrone (C)

Department of Urology, Policlinico San Martino Hospital, University of Genova, Genova, Italy.

Kees Hendricksen (K)

Department of Urology, Antoni van Leeuwenhoek Hospital, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Wojciech Krajewski (W)

Department of Minimally Invasive and Robotic Urology, Wrocław Medical University, Wrocław, Poland.

Oscar Buisan (O)

Department of Urology, Hospital Germans Trias I Pujol, Badalona, Spain.

Ekaterina Laukhtina (E)

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Vienna, Austria; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia.

Evanguelos Xylinas (E)

Urology Department, Bichat-Claude Bernard Hospital, Assistance-Publique Hôpitaux de Paris, Paris University, Paris, France.

Mario Alvarez-Maestro (M)

Department of Urology, Hospital Universitario La Paz, Madrid, Spain.

Morgan Rouprêt (M)

Sorbonne University, GRC 5 Predictive Onco-Uro, AP-HP, Urology, Pitie-Salpetriere Hospital, Paris, France.

Rodolfo Montironi (R)

Molecular Medicine and Cell Therapy Foundation, Department of Clinical and Molecular Sciences, Polytechnic University of the Marche Region,Ancona, Italy.

Marco Moschini (M)

Department of Urology, Luzerner Kantonsspital, Lucerne, Switzerland; Department of Medical Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH